国泰海通证券股份有限公司 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为北 京凯因科技股份有限公司（以下简称"凯因科技"、"公司"或"发行人"）首次 公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证券交 易所科创板股票上市规则》等有关法律法规和规范性文件的要求，就凯因科技使 用暂时闲置募集资金进行现金管理的事项进行了审慎核查，并发表如下核查意 见: 一、募集资金基本情况 经中国证券监督管理委员会《关于同意北京凯因科技股份有限公司首次公开 发行股票注册的批复》（证监许可〔2021〕8 号）核准，公司首次公开发行股票 4,246 万股，每股发行价格为人民币 18.98 元，募集资金总额为人民币 80,589.08 万元，扣除各项发行费用后实际募集资金净额为人民币 72,586.61 万元。上述募 集资金到位情况已经中汇事务所（特殊普通合伙）验证，并由其出具中汇会验 [2021]0208 号《验资报告》。 上述募集资金已全部存放 ...

北京凯因科技股份有限公司 审计报告 2024 年度 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel0571-88879999 Fax.0571-88879000 www.zhcpa.cn from 201 合由具有护 您可使用手机"扫一扫"或进入"注册 M | | 页 次 | | --- | --- | | 一、审计报告 | 1-6 | | 二、财务报表 | 1-12 | | (一) 合并资产负债表 | 1-2 | | (二) 合并利润表 | ങ | | (三) 合并现金流量表 | বা | | (四) 合并所有者权益变动表 | 5-6 | | (五) 母公司资产负债表 | 7-8 | | (六) 母公司利润表 | 9 | | (七) 母公司现金流量表 | 10 | | (八) 母公司所有者权益变动表 | 11-12 | 三、财务报表附注 13-108 四、事务所执业资质证明 中国杭州 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 231,594,549.40, representing an increase of 8.90% compared to CNY 212,673,809.18 in the same period last year[3] - Net profit attributable to shareholders was CNY 25,668,499.89, up 15.92% from CNY 22,144,168.59 year-on-year[3] - The basic earnings per share increased to CNY 0.15, reflecting a growth of 15.38% compared to CNY 0.13 in the same period last year[3] - The weighted average return on equity rose to 1.38%, an increase of 0.13 percentage points from the previous year[3] - The total comprehensive income for Q1 2025 was ¥25,457,646.89, compared to ¥24,435,627.84 in Q1 2024, indicating a year-over-year increase of 4.18%[20] Cash Flow - The net cash flow from operating activities improved significantly to CNY 5,867,946.35, compared to a negative cash flow of CNY 21,401,412.37 in the previous year[3] - Cash inflow from operating activities in Q1 2025 was ¥306,415,268.60, compared to ¥254,799,484.90 in Q1 2024, marking a rise of 20.25%[23] - The net cash flow from investing activities was -$6,546,054.13, an improvement from -$41,820,838.82 year-over-year[24] - Cash inflows from investing activities increased to $320,225,602.20, compared to $214,373,286.29 in the previous year[24] - The net cash flow from financing activities was -$4,962,686.72, a decline from a positive cash flow of $53,399,639.61 in the previous year[24] Expenses - Research and development expenses totaled CNY 26,277,546.81, a decrease of 9.58% from CNY 29,061,914.47, with R&D expenses accounting for 11.35% of revenue, down from 13.67%[4] - Total operating costs for Q1 2025 were ¥203,783,050.51, up from ¥191,738,956.41 in Q1 2024, reflecting a year-over-year increase of 6.18%[18] - The company reported a decrease in sales expenses to ¥114,742,965.35 in Q1 2025 from ¥103,972,619.47 in Q1 2024, showing improved cost management[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,520,928,379.89, a decrease of 3.62% from CNY 2,615,625,220.30 at the end of the previous year[4] - Total current assets decreased from CNY 1,860,100,437.22 as of December 31, 2024, to CNY 1,766,807,100.13 as of March 31, 2025, representing a decline of approximately 5.0%[12] - Total liabilities decreased to ¥612,302,223.30 in Q1 2025 from ¥735,327,270.60 in Q1 2024, a reduction of approximately 16.73%[15] - Total equity attributable to shareholders increased to ¥1,875,027,245.21 in Q1 2025 from ¥1,843,247,304.90 in Q1 2024, reflecting a growth of 1.73%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,805[8] - The largest shareholder, Beijing Song'an Investment Management Co., Ltd., held 22.46% of the shares, totaling 38,400,000 shares[8] Inventory and Fixed Assets - Inventory increased from CNY 144,238,608.29 to CNY 156,820,240.98, reflecting an increase of approximately 8.7%[13] - Fixed assets increased from CNY 245,864,224.69 to CNY 423,339,967.97, an increase of approximately 72.2%[13] - The company’s cash outflows for the acquisition of fixed assets and intangible assets were $12,771,656.33, significantly lower than $51,194,125.11 in the prior year[24]

Financial Performance - The company's operating revenue for 2024 was approximately ¥1.23 billion, a decrease of 12.87% compared to ¥1.41 billion in 2023[24]. - Net profit attributable to shareholders for 2024 was approximately ¥142.37 million, an increase of 22.18% from ¥116.52 million in 2023[24]. - The net profit after deducting non-recurring gains and losses for 2024 was approximately ¥136.98 million, up 11.75% from ¥122.58 million in 2023[24]. - The net cash flow from operating activities for 2024 was approximately ¥104.29 million, a decrease of 17.63% compared to ¥126.60 million in 2023[24]. - The total assets at the end of 2024 were approximately ¥2.62 billion, an increase of 6.84% from ¥2.45 billion at the end of 2023[24]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥1.84 billion, reflecting a growth of 5.10% from ¥1.75 billion at the end of 2023[24]. - The company's operating revenue for 2024 was CNY 1,230.30 million, a decrease of 12.87% compared to 2023, primarily due to price reductions following the implementation of centralized procurement policies for key products[27]. - Basic and diluted earnings per share for 2024 were CNY 0.85, reflecting a year-on-year growth of 21.43%[27]. - The weighted average return on equity increased to 7.93% in 2024, up by 1.12 percentage points from 2023[27]. Dividend Distribution - The company plans to distribute a cash dividend of 3.00 CNY per 10 shares, totaling approximately 50.23 million CNY, which represents 35.28% of the net profit attributable to shareholders[6]. - The profit distribution plan has been approved by the board and will be submitted for shareholder approval at the 2024 annual general meeting[7]. Corporate Governance - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures regarding external guarantees[9]. - The company has not disclosed any special arrangements for corporate governance[9]. - The board of directors, supervisory board, and senior management confirm the authenticity, accuracy, and completeness of the annual report[3]. - The company is committed to maintaining high standards of corporate governance, as evidenced by the stability in its board composition[167]. Research and Development - Research and development expenses accounted for 12.79% of operating revenue in 2024, an increase of 0.57 percentage points compared to the previous year[27]. - The company maintained a high R&D investment, totaling CNY 157.41 million, which accounted for 12.79% of operating revenue, and applied for 9 invention patents during the reporting period[40]. - The company has developed innovative drugs such as the pan-genotype oral drug and interferon α-2 injection, which have been industrialized successfully[44]. - The company has established a multi-target, multi-mechanism R&D pipeline in the field of viral hepatitis treatment, including projects KW-001, KW-027, and KW-040[68]. - The company has a total of 453 intellectual property rights, including 264 granted[65]. Market Strategy - The company follows a "sales-driven production" strategy, adjusting production plans based on market demand and sales forecasts[50]. - The company has established a comprehensive distribution system by collaborating with qualified pharmaceutical distributors across the country[51]. - The company is focused on expanding its product offerings in the pharmaceutical sector, particularly in the treatment of chronic hepatitis C[123]. - The company aims to accelerate the launch of new products and increase market share in 2025, focusing on innovative drug development and sales growth[152]. Regulatory Compliance - The company received an administrative regulatory measure decision from the China Securities Regulatory Commission on December 19, 2024[182]. - The company held meetings to address prior accounting errors and submitted a rectification report as required by the regulatory decision[183]. - The company disclosed corrected financial reports for the first three quarters of 2023 on December 20, 2024[183]. - The company has faced penalties from regulatory bodies in the past three years, necessitating corrective actions[182]. Employee and Management Information - The total compensation for the board members and senior management during the reporting period amounted to CNY 2,386.52 million[168]. - The company has a total of 600 employees, with 383 in the parent company and 217 in major subsidiaries[196]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 21.39 million RMB[179]. - The company has retained key personnel in core technology roles, ensuring continuity in its strategic direction and innovation efforts[169]. Future Outlook - The company provided an optimistic outlook for the next quarter, projecting revenue growth of 25% and aiming for $1.875 billion[170]. - The company plans to enhance its core competitiveness by focusing on innovative drug development for hepatitis B functional cure and immune disease prevention[132]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $100 million allocated for potential deals[170].

一、主要会计数据和财务指标 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 北京松安投资管理有限公司 | 3840.00 | 22.46 | 不变 | | 中庚价值先锋股票 | 633.45 | 3.71 | 280.37 | | 中庚价值领航混合 | 481.41 | 2.82 | 47.23 | | 易方达基金管理有限公司-社保基金17042组合 | 465.18 | 2.72 | 145.58 | | 毛顺华 | 317.95 | 1.86 | 新进 | | 北京富山湾投资管理中心(有限合伙) | 315.66 | 1.85 | 不变 | | 北京富宁湾投资管理中心(有限合伙) | 311.31 | 1.82 | 不变 | | 中庚价值品质一年持有期混合 | 293.55 | 1.72 | 10.00 | | 易方达新经济混合 | 243.31 | 1.42 | -70.45 | | 易方达科翔混合 | 241.08 | 1.41 | -99.28 | | 较上个报告期退出前十大股东有 | ...

Core Insights - The company reported a revenue of 1.23 billion yuan for 2024, with a net profit of 142 million yuan, marking a year-on-year growth of 22.18% [1] - In Q1 2025, the company achieved a revenue of 232 million yuan, reflecting an 8.90% year-on-year increase, and a net profit of approximately 25.67 million yuan, up 15.92% year-on-year [1] - The company maintained a high R&D investment intensity, with R&D expenditures of 157 million yuan in 2024, accounting for 12.79% of revenue, an increase of 0.57 percentage points year-on-year [1] R&D Progress - The company made significant advancements in several R&D projects during the reporting period, including the completion of Phase III clinical trials for KW-001 and the submission of a drug registration application [1] - KW-045 completed treatment and follow-up for all participants in its Phase IIa clinical trial for pediatric herpes pharyngitis [1] - KW-051 and KW-053 also progressed in their respective clinical trials, with KW-053 receiving approval for Phase II trials [1] Patent Activity - In 2024, the company applied for 9 invention patents and received authorization for 7, bringing the total to 175 applications and 60 authorized patents by the end of the reporting period [2] Capacity and Facility Upgrades - The company is advancing its antibody production base project, which has been included in Beijing's key engineering plans, with the main structure completed [3] - The company is upgrading its oral solid dosage production line and expanding capacity to accommodate future product launches [3] - The company is committed to enhancing its R&D capabilities and technical platform while focusing on innovative drug development and international collaboration [3]

中国经济网北京4月22日讯凯因科技(688687.SH)昨晚发布关于股东减持股份计划的公告显示，公司于近 日收到北京富山湾投资管理中心(有限合伙)(简称"富山湾")、北京富宁湾投资管理中心(有限合伙)(简 称"富宁湾")、北京卓尚石投资管理中心(有限合伙)(简称"卓尚石")、北京卓尚湾企业管理中心(有限合 伙)(简称"卓尚湾")出具的《股份减持计划告知函》。 富山湾、富宁湾、卓尚石、卓尚湾因其持有人自身资金需求，拟通过集中竞价及大宗交易的方式减持其 所持有的公司股份合计不超过5,128,000股，即不超过公司总股本的3.00%。自减持计划公告之日起15个 交易日后的3个月内(2025年5月16日至2025年8月15日)实施。 上述股份的减持价格均根据市场价格确定，若在减持计划实施期间公司发生派息、送股、资本公积转增 股本、配股等除权除息事项，将根据股本变动对减持数量进行相应调整。 公司实际控制人周德胜承诺不通过本次减持计划减持其间接持有的公司股份。 2024年2月3日，凯因科技发布以简易程序向特定对象发行人民币普通股股票预案。凯因科技本次以简易 程序向特定对象发行人民币普通股股票总额不超过人民币30,000. ...

1. 优德精密(300549.SZ)：持股5%以上股东UCM计划在公告后15个交易日起3个月内通过集中竞价交易 减持不超1,333,400股，占总股本1%。 2. 聚赛龙(301131.SZ)：股东东台聚合盈计划在公告后15个交易日起3个月内通过集中竞价减持不超 477,909股，占总股本1%。 3. 金丹科技(300829.SZ)：股东首中教育拟在公告后15个交易日起3个月内通过集中竞价减持不超60万 股，占总股本0.31%。 4. 智迪科技(301503.SZ)：股东昭华投资计划在公告后15个交易日起3个月内通过集中竞价或大宗交易减 持不超336,000股，占总股本0.42%。 5. 南极光(300940.SZ)：股东锦福源五号基金于4月21日持股比例降至4.9999%，不再为持股5%以上股 东。 6. 亚士创能(603378.SH)：董事及高管沈刚、徐志新、王永军减持计划完成，分别减持3,311,900股、 406,700股、319,300股。 7. 宝立食品(603170.SH)：股东上海厚旭在减持期间内未减持股份，原计划减持不超12,000,300股。 10. 税友股份(603171.SH)：控股股 ...

证券代码：688687 证券简称：凯因科技 公告编号：2025-002 北京凯因科技股份有限公司 关于股东减持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 股东持有的基本情况 截至本公告披露日，北京凯因科技股份有限公司（以下简称"公司"）股东： 北京富山湾投资管理中心（有限合伙）（以下简称"富山湾"）直接持有公司股份 3,156,600 股，占公司总股本的 1.85%；北京富宁湾投资管理中心（有限合伙） （以下简称"富宁湾"）直接持有公司股份 3,113,100 股，占公司总股本的 1.82%； 北京卓尚石投资管理中心（有限合伙）（以下简称"卓尚石"）直接持有公司股份 1,673,300 股，占公司总股本的 0.98%；北京卓尚湾企业管理中心（有限合伙） （以下简称"卓尚湾"）直接持有公司股份 1,043,922 股，占公司总股本的 0.61%。 富山湾、富宁湾、卓尚石、卓尚湾均属于公司实际控制人能够控制的企业，上述 股东合计持有公司股份 8,986,922 股，占公司总股本的 ...

凯因科技公告，股东富山湾、富宁湾、卓尚石、卓尚湾因持有人自身资金需求，计划通过集中竞价及大 宗交易方式减持公司股份不超过512.8万股，即不超过公司总股本的3.00%。减持期间为2025年5月16日 至2025年8月15日。减持价格将根据市场价格确定。 ...